Hepatocellular Carcinoma  SITC CPG Mini Module - Front-Line Management for Advanced Hepatocellular Carcinoma

The SITC Cancer Immunotherapy Guidelines Webinars connect clinicians with leading experts in the field and provide education about the evidence- and consensus-based recommendations in the clinical practice guidelines. To complement the advanced live webinar series, three on-demand, mini modules will assist learners in applying lessons learned on specific topics within the use of immunotherapy in their own practices and locate additional resources to continue their education.   

This mini module begins with a case study presented by Ahmed O. Kaseb, MD - The University of Texas MD Anderson Cancer Center, on the use of atezolizumab and bevacizumab to treat advanced hepatocellular carcinoma (HCC).  Results from the IMbrave 150 clinical trial, immune-related adverse effects, and HCC treatment sequencing options are also presented.  The mini module ends with a panel discussion of important considerations when choosing first-line treatment of HCC. 

Run time: 12 minutes, 34 seconds 

Target Audience 

Clinicians and advanced practice providers who treat cancer patients are the target audience, including community physicians, oncologists, emergency room physicians, disease specialists, registered nurses, nurse practitioners, pharmacists, physician assistants and radiologists. 

SITC Online Education Disclaimer 

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

The Quick Education Modules are part of the Cancer Immunotherapy Clinical Practice Guidelines Advanced Webinar Series supported, in part, by grants from Amgen and Merck & Co., Inc. (as of 9/20/2021). 
 
The SITC Clinical Practice Guidelines are produced and funded solely by SITC. No outside funding is received for the development of the manuscripts.